Durvalumab (Nurse)
Medication Basics
Drug Name
Durvalumab (Brand names: Imfinzi®)
Purpose / Indication
Used to treat certain cancers, including lung cancer, biliary tract cancer, hepatocellular carcinoma, and other approved oncology indications as directed by the care team. Verify indication, regimen, line of therapy, biomarker requirements, and institutional protocol before administration.
Dosage & Administration
Dose Schedule
Administered as an intravenous infusion on a schedule determined by cancer type, combination regimen, weight, and protocol; common schedules include every 2, 3, or 4 weeks.
Route
IV (Intravenous)
Timing Considerations
Confirm treatment plan, cycle timing, combination agents, hold parameters, infusion duration, and any required pre-infusion assessments before administration.
Time of Day
Flexible
Special Instructions
Assess baseline symptoms, review labs, confirm consent, educate on immune-related or targeted-therapy toxicities, and follow institutional hypersensitivity/infusion reaction procedures.
Injection Techniques
Administer by IV infusion per institutional policy and current prescribing information. Do not administer IV push or bolus unless specifically supported by policy.
Mechanism of Action
Mechanism
Durvalumab is a PD-L1 blocking antibody that prevents PD-L1 binding to PD-1 and CD80, enhancing antitumor immune responses while preserving PD-L2/PD-1 interaction.